GlycoMimetics, Inc. Profile Avatar - Palmy Investing

GlycoMimetics, Inc.

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inh…

Biotechnology
US, Rockville [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

GlycoMimetics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of GLYC's Analysis
CIK: 1253689 CUSIP: 38000Q102 ISIN: US38000Q1022 LEI: - UEI: -
Secondary Listings
GLYC has no secondary listings inside our databases.